Benchmark has closed a $2 billion capital raise and created its first-ever growth fund, marking a significant shift from the firm's 20-year tradition of maintaining fund sizes around $425 million.
The legendary venture capital firm is expanding its strategy with the new growth fund as part of its largest capital raise to date. The move breaks from Benchmark's long-standing approach of keeping its funds at relatively modest sizes compared to mega-funds that have become commonplace in recent years.
Benchmark, known for early-stage investments in companies like Uber, Instagram, and Snapchat, has historically focused on seed and Series A funding rounds. The introduction of a dedicated growth fund signals the firm's intention to participate in later-stage rounds alongside its core early-stage operations.
The $2 billion raise comprises capital for multiple funds, with the new growth vehicle representing a notable expansion of Benchmark's investment capacity. The firm has attracted commitments from institutional investors, reflecting continued confidence in its track record and investment thesis.
This capital raise positions Benchmark to deploy larger checks in scaling companies while maintaining its presence in the earlier funding stages where it built its reputation. The move reflects broader trends in venture capital, where many established firms are diversifying their fund portfolios to capture value across multiple growth stages.
Benchmark's decision to launch a growth fund also comes as competition intensifies among top-tier venture firms for allocation in high-growth companies. By expanding its fund offerings, the firm can provide more comprehensive support to portfolio companies seeking growth capital without relying on external partners.
The firm's fundraising success demonstrates investor appetite for established venture players with proven returns and brand recognition in startup investing.
Colorado-based biotech startup Enveda, which uses AI to discover new drugs from natural sources, secured $311 million in Series E funding at a $2 billion valuation—double its valuation from a year ago.
Modal Labs and Baseten, two platforms enabling businesses to run AI models, are in advanced funding talks that would significantly boost their valuations. The rounds reflect growing investor appetite for AI infrastructure services.
Ema, an AI agent platform automating corporate processes in HR, IT, and finance, secured $77 million in Series B funding led by Creaegis. The round brings the startup's total funding to $140 million.
Enveda Therapeutics raised $311 million in funding, bringing the AI biotech company's valuation to $2 billion. The capital will accelerate clinical trials for drugs derived from natural compounds.